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Abstract: Renal retransplant patients have decreased graft survival compared to primary renal 
transplant patients. Alemtuzumab induction is often used at the time of retransplant; however, the 
literature surrounding alemtuzumab induction in renal retransplant patients is limited. In this single-
center, retrospective, observational study, we aimed to determine the one-year incidence of infections 
and transplant outcomes in renal retransplant patients who received alemtuzumab induction. Thirty-
four patients who received alemtuzumab met inclusion criteria and were included in the final analysis. 
Twenty-two (64.7%) of these patients acquired infections. Of these, seven patients (31.8%) acquired 
infections that resulted in hospitalization or IV antibiotics. The most common infections were urinary 
tract infections (UTIs) (n=10; 29.4%), cytomegalovirus DNAemia (n=7; 20.6%), and BK virus (n=6; 17.6%). 
The number of patients who developed de novo donor specific antibodies (DSA) was n=11 (32.4%) with 
only one of these patients having DSA prior to retransplantation. The incidence of acute cellular 
rejection was 2.9% (n=1). There was no graft loss, and patient survival was 97% (n=33). There were no 
significant differences in infection rate or DSA development between alemtuzumab and the other 
induction agents, anti-thymocyte globulin (ATG) and basiliximab, among retransplanted patients. 
Alemtuzumab induction in renal retransplant patients resulted in similar bacterial and viral infection 











 Long-term renal allograft survival is limited with an estimated half-life of 8.8 years for deceased 
donors and 11.9 years for living donors.1 Unfortunately, many patients receiving an initial renal 
transplant will eventually require additional transplantation. The United Network for Organ Sharing 
(UNOS) reported that 12,265 patients out of the 99,643 patients awaiting a kidney in 2020 were 
retransplants.2 Compared to primary renal transplant patients, those with repeat transplantations have 
decreased graft survival.3 Nevertheless, a repeat renal transplant is significantly higher than those 
returning to dialysis following graft failure.4  
Common reasons for graft loss include acute rejection, chronic rejection, calcineurin inhibitor 
nephrotoxicity, and BK virus infection.5,6 Following transplantation, a patient may develop donor specific 
antibodies (DSA) against the allograft, increasing the risk of acute rejection. Because of this, retransplant 
patients are often sensitized and have an increased rate of acute rejection compared to primary 
transplant patients.7 Lymphodepleting agents, such as alemtuzumab, are commonly used over IL-2 
blockers in retransplant patients to offset this increased risk of acute rejection.8 
 Retransplantation is a growing segment of the transplant population with unique challenges 
that merit specific study. Despite the growing number of renal retransplant patients, many researchers 
have excluded this patient population from their clinical research trials.  The literature surrounding 
induction with alemtuzumab, a humanized monoclonal antibody targeting CD52 on lymphocytes, in this 
population is limited.9-11 Alemtuzumab is associated with an increased risk of DSA development 
compared to anti-thymocyte globulin (ATG) and interleukin-2 (IL-2) receptor blockers, possibly due to its 
unique ability to deplete peripheral B cells.12 No study to date has addressed de novo DSA development 
in renal retransplant patients receiving alemtuzumab induction and the effects of this on graft rejection 
and other transplant outcomes. It is proposed that cumulative doses of lymphodepleting induction 




transplant patients. To date, only limited data exists concerning infectious risk of alemtuzumab 
induction in renal retransplant patients.10,11 The purpose of this study was to determine the incidence of 
alemtuzumab associated infections (bacterial, viral, fungal, and opportunistic infections) and to assess 
transplant outcomes in renal retransplant patients within 12 months of retransplant. 
 
2. METHODS 
2.1 Study Participants 
 This observational, retrospective cohort study included adult kidney retransplant patients who 
received induction with alemtuzumab, ATG, or basiliximab between April 1, 2014 and November 1, 2018 
at a single, academic transplant center. Patients were excluded if they underwent a dual or ABO-
incompatible transplant. This study was approved by the institutional Investigational Review Board.  
 
2.2 Immunosuppression/Post-transplant Care  
 All patients included in the study received induction therapy with one of the following agents: 
alemtuzumab (Campath-1H; Genzyme Corporation, Cambridge, MA) 30 mg IV and methylprednisolone 
500 mg IV intraoperatively with a rapid steroid withdrawal by post-operative day four, anti-thymocyte 
globulin (Thymoglobulin; Genzyme Corporation, Cambridge, MA) 6 mg/kg IV given over 3 days (post-
operative days 0, 1, and 2) at 2 mg/kg/day and methylprednisolone 500mg IV intraoperatively, 
basiliximab (Simulect, Novartis Pharmaceuticals Corporation, East Hanover, NJ) 20 mg IV given 
intraoperatively and on post-operative day 4 and methylprednisolone 500mg IV intraoperatively. The 
choice of induction agent and the use of maintenance oral steroids following retransplantation was 
based on patient specific factors and determined by the solid organ transplant team and the institution’s 
immunosuppression protocol. Maintenance immunosuppression consisted of tacrolimus (Prograf; 




Hanover, NJ) and a mycophenolic acid derivative (Myfortic; Novartis Pharmaceuticals Corporation, East 
Hanover, NJ) at 540 mg by mouth twice daily or the equivalent mycophenolate mofetil dose (Cellcept; 
Genetech USA, Inc, South San Francisco, CA). Variations in maintenance immunosuppression from the 
standard regimen were made by the transplant provider on an individual basis. All calcineurin inhibitor 
(CNI) trough concentrations included in the analysis were drawn before the morning dose to obtain a 
12-hour trough concentration and evaluated by our laboratory using liquid chromatography-mass 
spectrometry. Goal therapeutic trough ranges for tacrolimus were 8-10 ng/mL for months 0-3 and 6-8 
ng/mL for months 4-12. Pneumocystis jiroveci pneumonia prophylaxis included 
sulfamethoxazole/trimethoprim 400mg/80mg by mouth daily as the first line option for 6 months 
following transplant. Cytomegalovirus (CMV) prophylaxis included acyclovir for 3 months for low-risk 
patients (donor - / recipient -), valganciclovir for 3 months for moderate-risk patients (donor + / 
recipient + or donor - / recipient +), and valganciclovir for 6 months for high-risk patients (donor + / 
recipient -). Thrush prophylaxis consisted of nystatin 10 mL (1,000,000 units) by mouth three times daily 
during inpatient stay. 
 
2.3 Variables of Interest, Outcomes, and Definitions 
 The institutional electronic health record was utilized for data collection. The primary endpoint 
was the incidence of infections (bacterial, viral, fungal, and opportunistic infections) within 12 months of 
retransplantation with alemtuzumab induction. Infections excluded from the primary endpoint were 
pneumonia, cellulitis, and other skin and soft tissue infections. These infections were excluded from the 
primary endpoint due to reliance on clinician discretion for diagnosis, potentially leading to false-
positives and false-negatives results.  BK viruria and viremia were defined as the presence of BK virus in 
the urine or blood samples, respectively, as determined by PCR.13 The cut off value for BK viruria and 




copies/mL for patients who were treated for BK viremia based on clinician discretion. BK virus 
nephropathy (BKVN) was defined as confirmed positive renal biopsy for BKVN and histology 
characterized by tubular atrophy and fibrosis with an inflammatory lymphocytic infiltrate.13 CMV 
DNAemia was defined as a positive quantitative nucleic acid amplification.14 The cut off value for CMV 
DNAemia was designated as CMV ≥ 1000 IU/mL for asymptomatic patients or CMV ≥200 IU/mL for 
patients who were treated for CMV DNAemia based on clinician discretion. Bacteremia was defined as 
two out of two blood cultures positive for the same bacterial species from central line and/or peripheral 
line. Urinary tract infection (UTI) was defined as urine cultures that contained ≥105 colony forming units 
(CFU)/mL of the same organism.15 Clostridium difficile (C. difficile) was defined as a positive PCR/nucleic 
acid amplification test (NAAT) for toxigenic C. difficile in stool samples.16 Other infections that were 
included in the primary endpoint were influenza, Epstein-Barr Virus (EBV), Herpes Simplex Virus (HSV), 
Varicella Zoster Virus (VZV) and fungal infections (aspergillosis, histoplasmosis, coccidioidomycosis, 
blastomycosis, mucormycosis, cryptococcosis, pneumocystis jiroveci pneumonia). These opportunistic 
infections were defined based on treatment guidelines.17-23 
 The secondary endpoints consisted of acute rejection, patient and graft survival, and 
development of de novo DSA within 12 months of retransplantation with alemtuzumab.  Additional 
secondary endpoints included the presence of infections, acute rejection, patient and graft survival, and 
development of de novo DSA within 12 months of retransplantation with ATG induction, and the 
presence of infections, acute rejection, patient and graft survival, and development of de novo DSA 
within 12 months of retransplantation with basiliximab induction. Acute rejection was defined as either 
acute cellular rejection (ACR), antibody-mediated rejection (AMR), or mixed acute rejection as 
determined by renal biopsy. Development of de novo DSA was defined as the development of new anti-







2.4 Statistical Analysis 
 Descriptive statistics were used to determine the primary and secondary endpoints. Categorical 
values were reported as counts and percentage of the population and continuous values were reported 
as median (minimum – maximum). The Fisher’s Exact Test was used to detect statistical differences in 
outcomes between alemtuzumab and the other induction agents used in the study, ATG and 
basiliximab.  A p-value of less than 0.05 was considered statistically significant. Statistical analyses were 
performed using SPSS Statistics 26 (Armonk, NY).   
 
3. RESULTS 
3.1. Cohort Characteristics 
 During the study period, 45 patients received a renal retransplant and were included in the final 
analysis: 34 patients received alemtuzumab induction, five patients received ATG induction, and six 
patients received basiliximab induction. Patient characteristics are listed in Table 1. Many of the patients 
were sensitized in the alemtuzumab group with n=15 (44.1%) having cPRA between 80-100% and n=11 
(32.4%) developing DSA after receiving the first renal transplant. No patients receiving ATG had DSA at 
any point prior to retransplant whereas approximately one-third of the patients who received 
basiliximab (n=2; 33.3%) had DSA prior to retransplant. The median time in between subsequent 
transplants in the alemtuzumab group was 171 months. The majority of patients received 
tacrolimus/mycophenolate mofetil (MMF) dual therapy or tacrolimus/MMF/prednisone triple therapy 






3.2 Infectious Outcomes 
Of the 34 patients included in the alemtuzumab group, 22 (64.7%) acquired infections within 12 
months of retransplantation (Table 3). Of these, seven patients (31.8%) acquired infections that resulted 
in hospitalization or IV antibiotics. Seven patients (20.6%) acquired CMV DNAemia and six patients 
(17.6%) acquired BK virus. Of these, three patients had BK viremia, two patients had BK virus 
nephropathy, and one patient had BK viruria. One patient acquired adenovirus 169 days after 
retransplantation and one patient acquired rhinovirus 358 days after retransplantation. Ten patients in 
the alemtuzumab group (29.4%) acquired urinary tract infections (UTIs). Of these ten patients, three 
patients acquired two UTIs each within 12 months. The organisms that were isolated include Escherichia 
coli (n=4), Klebsiella pneumoniae (n=3), Staphylococcus epidermidis (n=2), Candida albicans (n=1), 
Candida glabrata (n=1), Enterobacter (n=1), and Pseudomonas aeruginosa (n=1).  One patient acquired 
Escherichia coli bacteremia caused by dissemination of UTI 63 days after retransplantation. One patient 
acquired Clostridium difficile 97 days after retransplantation. Of the five patients who received ATG, one 
(20%) acquired an infection, BK viremia, within 12 months of retransplantation (Table 3). Of the six 
patients who received basiliximab induction, four (66.7%) acquired infections within 12 months of 
retransplantation (Table 3). One patient in the basiliximab group acquired CMV DNAemia, one patient 
acquired BK viruria, one patient acquired adenovirus, and one patient acquired Epstein-Barr Virus.  The 
total number of infections acquired in the alemtuzumab group was not significantly different from the 
number acquired in the ATG group (p=0.139) or the basiliximab group (p=1.000). 
 
3.3 Infectious Outcomes Associated with Steroid Use 
 The number of patients who received alemtuzumab induction and on maintenance prednisone 
at the time of transplant, 3 months, 6 months, 9 months, and 12 months following retransplant were 




prednisone dose for those on maintenance steroids was 7.1 mg ± 7.2 mg at time of transplant, 5.9 mg ± 
2.0 mg at 3 months, 5.6 mg ± 1.7 mg at 6 months, 7.5 mg ± 8.8 mg at 9 months, and 5.4 mg ± 1.8 mg at 
12 months post-transplant.  Of the 22 patients who developed an infection within 12 months of 
retransplantation, eleven (50%) had received steroids prior to or during the time that they acquired 
their infection. The two patients who developed BK nephropathy were on maintenance steroids at the 
time of diagnosis. The remaining eleven patients (50%) who acquired an infection within 12 months of 
retransplantation did not receive maintenance steroids. The majority of the infections in the steroid free 
group were UTIs (n=7; 53.8%) and the majority of the infections in the steroid maintenance group were 
viral (n=10; 71.4%); however, the difference in the rate in viral infections between the two groups was 
not significant (p=0.128). Additional infections that occurred are shown in Figure 1.  
 
3.4 Transplant Outcomes 
 The incidence of acute cellular rejection within 12 months of retransplantation with 
alemtuzumab induction was 2.9% (n=1) and occurred 49 days after retransplant. No patients developed 
antibody mediated rejection or mixed rejection. Eleven patients (32.4%) developed de novo DSA 
towards their retransplanted renal graft within 12 months of retransplantation with alemtuzumab with 
only one of these patients having DSA at any point prior to retransplantation. The average time to de 
novo DSA development was 130 days, and the average MFI was 3,492 (1,186 – 20,075). There was no 
graft loss, and patient survival was 97% (n=33) with one death due to unknown causes within 12 months 
of retransplantation with alemtuzumab. There was no acute rejection and graft and patient survival was 
100% in both the ATG and basiliximab induction groups. Two patients in the ATG group and one patient 
in the basiliximab group developed DSA within 12 months of retransplantation with none of these 




novo DSA in the alemtuzumab group was not significantly different from the ATG group (p=1.000) or the 
basiliximab group (p=0.648). 
 
4. DISCUSSION 
 The most common infections acquired in our cohort were urinary tract infections, CMV 
DNAemia, and BK viremia. No patients experienced invasive fungal infections (candidiasis, PJP, 
aspergillus, mucor, etc). This is in contrast to a recent retrospective study by Descourouez et al that 
reported a substantial number of fungal infections (46.8%) and bacterial infections (18.7%) in renal 
retransplant patients that received alemtuzumab induction.11 However, several factors were different 
between this study and our study that might have impacted the difference in infection rates. First, the 
average time in between subsequent transplants for our patients was 170 months. In contrast, patients 
in the Descourouez et al study who received alemtuzumab for induction had an average of 20 months in 
between subsequent transplants. In addition, the majority of patients in the Descourouez et al study 
received two 30-mg doses of alemtuzumab for induction therapy whereas our center used a single 30mg 
dose of alemtuzumab for induction therapy. The higher dose of alemtuzumab, as well as the shorter 
time frame in between subsequent transplants, could be the reason why an increased proportion of 
patients experienced fungal and bacterial infections in the Descourouez et al studied compared to our 
study. 
A larger, retrospective study by Schold et al found the risk of BK virus for retransplant patients 
who received alemtuzumab was 4%.10 This is in contrast to our study which found 17.6% of patients 
acquired BK virus and is closer to the results in the Descourouez et al study that found the rate of BK 
virus to be 12.5%. Neither the Schold et al study nor the Descouroez et al study stratified patients based 
on steroid use during their analysis of infectious outcomes. Our study found that the use of maintenance 




steroid-free maintenance interval, indicating that the use of steroids for additional immunosuppression 
may not lead to negative outcomes from an infection standpoint.  
 Three retrospective studies were conducted that evaluated transplant outcomes in renal 
retransplant patients receiving alemtuzumab induction. The reported 1-year acute rejection rates in 
these studies were higher than the acute rejection rate of our study. Our study found a lower rate of 
rejection, 2.9%, compared to other studies (10-25%).9-11 The majority of the patients in our study did not 
have DSA prior to retransplant, which could account for the low acute rejection rate seen in our study. 
Approximately half of our patients were on maintenance steroids within 12 months of retransplant, 
which would result in greater immunosuppression and possibly less acute rejection compared to the 
other studies. However, approximately half of the patients who received alemtuzumab induction in the 
Santos et al study received maintenance steroids and almost all of the patients in the Schold et al and 
the Descourouez et al studies received maintenance steroids following alemtuzumab induction.  
 Our study was the first to analyze how the development of de novo DSA in renal retransplant 
patients who received alemtuzumab induction influenced acute rejection rates. Development of de novo 
DSA in the alemtuzumab group was 32.4% (n=11) with n=1 of these patients having DSA prior to 
retransplant. A similar rate of de novo DSA development has previously been reported in primary renal 
transplant patients. A study by Todeschini et al found 50% of primary renal transplant patients who 
received alemtuzumab induction developed de novo DSA within 12 months of transplant, despite no 
history of DSA prior to transplant.12 Similar to our study, none of the patients in the Todeschini et al 
study who developed DSA experienced antibody mediated rejection within 12 months of transplant. 
This suggests that, although retransplant patients have a higher chance of being sensitized compared to 
primary transplant patients, development of DSA following alemtuzumab induction may not lead to an 
increased risk of antibody mediated rejection in the short-term. Long-term follow-up is needed to see if 




 The limitations of this study are inherent to the design of a retrospective cohort study. 
Observational studies carry the risk for confounding bias. To reduce this bias, we performed 
stratification and analysis of subgroups that we thought may contribute to this type of bias, i.e. the use 
or absence of steroids for maintenance immunosuppression. Small sample sizes, particularly in the ATG 
and basiliximab treatment groups, may result in our study lacking adequate statistical power to note 
differences in outcomes between the alemtuzumab group and the ATG and basiliximab groups. With the 
knowledge gained from this project, it could add to the growing body of literature surrounding 
retransplant patients to help institutions assess the risks and benefits of choosing alemtuzumab as an 
induction agent. Future studies including larger sample sizes and longer follow-up would be warranted 
given the favorable outcomes in this study.   
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TABLES AND FIGURES 
 
Values are reported as median (range) or n (%) 
a: median (minimum – maximum) 
ATG: Antithymocyte globulin 
cPRA: calculated Panel Reactive Antibodies 
DSA: Donor Specific Antibodies 
 
Table 1. Clinical and Demographic Characteristics of Patients
N = 34 N = 5 N = 6
Baseline Characteristics Alemtuzumab ATG Basiliximab
Gender
      Male 22 (65%) 4 (80%) 3 (50%)
Race
      Caucasian 21 (61.8%) 2 (40%) 3 (50%)
      African American 10 (29.4%) 3 (60%) 2 (33.3%)
      Hispanic 2 (5.9%) 0 1 (16.7%)
      American Indian 1 (2.9%) 0 0
Agea 49 (25 - 66) 56 (52 - 65) 40 (22 - 56)
Etiology of Renal Disease
      Hypertension 6 (17.6%) 1 (20%) 0
      Diabetes 6 (17.6%) 2 (40%) 0
      Chronic Glomerulonephritis 3 (8.8%) 0 0
      IgA Nephropathy 4 (11.8%) 1 (20%) 1 (16.7%)
      ANCA Vasculitis 2 (5.9%) 0 0
      Goodpasture’s Syndrome 2 (5.9%) 0 0
      Interstitial Nephritis 2 (5.9%) 0 0
      Polycystic Kidney Disease 3 (8.8%) 0 1 (16.7%)
      Other 6 (17.6%) 1 (20%) 4 (66.7%)
Months between subsequent transplantsa 171 (27-306) 212 (69 - 257) 152 (53 - 302)
Reason for retransplant
      Chronic Rejection 19 (55.9%) 3 (60%) 1 (16.7%)
      Acute Rejection 6 (17.6%) 0 0
      Infections 2 (5.9%) 0 1 (16.7%)
      Rejection (Unknown Type) 2 (5.9%) 0 0
      Acute Tubular Necrosis 2 (5.9%) 0 0
      Calcineurin Inhibitor Toxicity 1 (2.9%) 0 1 (16.7%)
      Recurrent Disease 0 1 (20%) 2 (33.3%)
      Other 2 (5.9%) 1 (20%) 1 (16.7%)
cPRA at time of transplant
      0-20% 3 (8.8%) 0 2 (33.3%)
      20-40% 1 (2.9%) 0 0
      40-60% 4 (11.8%) 0 0
      60-80% 1 (2.9%) 0 0
      80-100% 15 (44.1%) 1 (20%) 0
      Not reported 10 (29.4%) 4 (80%) 4 (66.7%)
DSA prior to re-transplant 
      Yes 11 (32.4%) 0 2 (33.3%)
Donor relationship
      Living related 5 (14.7%) 2 (40%) 1 (16.7%)
      Living unrelated 6 (17.6%) 0 3 (50%)





Table 2: Maintenance Immunosuppression used in Alemtuzumab Patients 
Maintenance 
Immunosuppression 
At transplant  
N (%) 
3 months      
N (%) 
6 months    
N(%) 
9 months    
N(%) 
12 months  
N (%) 
Triple therapy (tac, pred, MMF) 12 (35.3%) 14 (41.2%) 13 (38.2%) 12 (35.3%) 14 (42.4%) 
Triple therapy (tac, pred, aza) 0 1 (2.9%) 1 (2.9%) 0 1 (3%) 
Dual therapy (tac, MMF) 22 (64.7%) 17 (50%) 16 (47.1%) 17 (50%) 15 (45.5%) 
Dual therapy (tac, aza) 0 0 0 1 (2.9%) 0 
Dual therapy (tac, pred) 0 1 (2.9%) 2 (5.9%) 3 (8.8%) 3 (9.1%) 
Dual therapy (siro, pred) 0 1 (2.9%) 1 (2.9%) 1 (2.9%) 0 

































Table 3: Infections within 12 Months of Retransplantation 
Infections 
Mean time to infection 
(min - max) (days) N (%) 
Mean viral copies (min - 
max) 
ALEMTUZUMAB    
Viral Infections    
CMV DNAemia 152 (22-282) 7 (20.6%) 4,463 IU/mL (315 - 13,183) 
BK Virus    
        BK Viremia 181 (92-346) 3 (8.8%)  24,347 copies/mL (2,400 - 35,641) 
        BK Viruria 197 1 (2.9%) 1,679,530 copies/mL 
        BK Nephropathy 137 2 (5.9%) - 
Other Viral    
        Adenovirus 169 1 (2.9%) - 
        Rhinovirus 358 1 (2.9%) - 
Bacterial Infections    
Urinary Tract Infection 126 (9-350) 10 (29.4%) - 
Bacteremia 63 1 (2.9%) - 
Clostridium difficile 97 1 (2.9%) - 
    
ATG    
      Viral Infections    
BK Viremia 252 1 (20%)  409 copies/mL 
    
BASILIXIMAB    
      Viral Infections    
CMV DNAemia 238 1 (16.7%) 40,641 IU/mL 
BK Virus    
        BK Viruria 274 1 (16.7%)  1,070,159 copies/mL 
Other Viral    
        Adenovirus 251 1 (16.7%)  - 













Figure 1. Infection Rate Based on the Use or Absence of Steroid Maintenance Therapy 








































UTI: Urinary Tract Infection 
BKV: BK Virus 
CMV: Cytomegalovirus 
 
 
 
